CRH Medical Corporation

June 17, 2016 12:00 ET

CRH Medical Announces Voting Results of Shareholders Meeting

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 17, 2016) - CRH Medical Corporation (the "Company") (TSX:CRH) (NYSE MKT:CRHM), announces the following voting results for the Company's 2016 Annual Meeting of Shareholders held yesterday (the "Meeting"). At the Meeting, the number of directors was set at five, the nominees listed in the Company's management proxy circular were elected as directors, and KPMG LLP was appointed as auditor of the Company for the coming year.

A total of 35,297,102 common shares of the 71,449,648 common shares outstanding were voted at the Meeting, representing approximately 49.40% of the issued and outstanding common shares of the Company. Detailed results of the vote for the election of directors are set out below:

Nominee Votes For % Votes For Votes Withheld % Votes Withheld
Dr. Anthony Holler 26,864,354 95.80 % 1,177,267 4.20 %
Dr. David Johnson 28,003,641 99.86 % 37,980 0.14 %
Todd Patrick 26,861,242 95.79 % 1,180,379 4.21 %
Ian Webb 26,861,784 95.79 % 1,179,837 4.21 %
Edward Wright 27,895,289 99.48 % 146,332 0.52 %

In addition, KPMG LLP was appointed auditor of the Company for the upcoming year, by a show of hands.

About CRH Medical Corporation:

CRH Medical Corporation is a North American company focused on providing physicians with innovative services and products for the treatment of gastrointestinal diseases. In 2014, CRH acquired a full service gastroenterology anesthesia company, Gastroenterology Anesthesia Associates, LLC ("GAA"), which provides anesthesia services for patients undergoing endoscopic procedures. CRH complemented five additional acquisitions of anesthesia companies during 2015 and continues to execute on its acquisition strategy in 2016. Anesthesia assisted endoscopies make these procedures more comfortable for patients and allow gastroenterologists to perform more procedures. CRH plans to leverage the capabilities it acquired through GAA to continue to consolidate the highly fragmented gastroenterology anesthesia provider business. The Company's product distribution strategy focuses on physician education, patient outcomes, and patient awareness. The Company's first product, the CRH O'Regan System, is a single use, disposable, hemorrhoid banding technology that is safe and highly effective in treating hemorrhoid grades I - IV. CRH distributes the CRH O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians, allowing CRH to create meaningful relationships with the physicians it serves. The Company's goal is to establish CRH as the premier provider of essential services and innovative products to gastroenterologists throughout the United States.

Contact Information